Bibliografia

1. Nichols J. Methadone maintenance therapy. Med J Aust 1990; 152(7): 389.

2. Douglas JG, Munro JF, Kitchin AH et al. Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) 1981; 283: 881-3.

3. McMurray J, Bloomfield P, Miller HC. Irreversibile pulmonary hypertension after treatment with fenfluramine. BMJ 1986; 293: 51-2.

4. Gotway MB, Shelley RM, Douglas KH et al. Thoracic conplications of illicit drug use: an organ system approach. Radiographics 2002; 22: S119-35.

5. Sweetman CS. Martindale: the complete drug reference. 33 ^rd ed. London, United Kingdom: Pharmaceutical Press, 2002.

6. Ligeiro-Oliveira AP, Fialho de Araujo AM, Lazzarini R et al. Effects of amphetamine on immune-mediated lung inflammatory response in rats. Neuroimmunomodulation 2004; 11(3): 181-90.

7. Khalsa ME, Tashkin DP, Perrochet B. Smoked cocaine: patterns of use and pulmonary consequences. J Psychoactive Drugs 1992; 24(3): 265-72.

8. Oh PI, Balter MS. Cocaine induced eosinophilic lung disease. Thorax 1992; 47(6): 478-9.

9. Siegel AJ, Sholar MB, Mendelson Jh et al. Cocaine-induced erythrocytosis and increase in Von Willebrand factor: evidence for drug-related blood doping and prothrombotic effects. Arch Intern Med 1999; 159: 1925-9.

10. Travis WD, Galvin JR. Non-neoplastic pulmonary lymphoid lesions. Thorax 2001; 56: 964-71.

11. Susskind H, Weber DA, Volkow ND et al. Increased lung permeability following long-term use of free-base cocaine (crack). Chest 199; 100 (4): 903-9.

12. Tashkin DP, Khalsa ME, Gorelick D et al. Pulmonary status of abitual cocaine smokers. Am Rev Respir Dis 1992; 145 (1): 92-100.

13. Perper JA, Van Thiel DH. Respiratotory complicantions of cocaine abuse. Recent Dev Alcohol 1992; 10: 363-77.

14. Martin BJ, Zwillich CE, Weil JL. Morphine reduces ventilation without changing metabolic rate in exercise. Med Sci Sports Exerc 1980; 12: 285.

15. Dettmeyer R, Schmidt P, Musshoff F et al. Pulmonary edema in fatal heroin overdose: immunohistological investigations with IgE, collagen IV and laminin - no increase of defects of alveolar-capillary membranes. Foren Sci Inter 2000; 110: 87-96.

16. Sporer KA, Dorn E. Heroin-related noncardiogenic pulmonary edema: a case series. Chest 2001; 120: 1628-32.

17. Paré JP, Cote G, Fraser RS. Long term follow-up of drug abusers with intravenous talcosis. Am Rev Respir Dis 1989; 139: 233-41.

18. Schmidt RA, Glenny RW, Godwin JD et al. Panlobular emphysema in young intravenous Ritalin abusers. Am Rev Respir Dis 1991; 143(3): 649-56.

19. Ward DS, Nitti GJ. The effects of sufentanil on the hemodynamic and respiratory response to exercise. Med Sci Sports Exerc 1988; 20(6): 579-86.

20. Adamson J. Erythropoietin, iron metabolism, and red blood cell production. Semin Hematol 1996; 33(2 Suppl 2): 5-7; discussion 8-9.

21. Storring PI, Tiplady RJ, Gaines Das RE et al. Epoietin alfa on beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79-89.

22. Wiesholzer M, Kitzwogeree M, Harm F et al. Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin. Am J Kidney Dis 1999; 33(4): 702-8.

23. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature 2000; 405(6787): 635.

24. Parisotto R, Wu M, Ashenden MJ et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erithropoiesis. Haematologica 2001; 86: 128-37.

25. Aschenden MJ, Hahn AG, Martin DT et al. A comparison of the physiological response to simulated altitude exposure and r-HuEpo administration. J Sport Sci 2001; 19: 831-7.

26. Bosanquet AG, Sturm I, Wieder T et al. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia 2002; 16(6): 1035-44.

27. Audran M, Gareau R, Matecki S et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc 1999; 31(5): 639-45.

28. Hoffmann D, Raineri R, Hecht SS et al. A study of tobacco carcinogenesis. XIV. Effects of N'-nitrosonornicotine and N'-nitrosonanabasine in rats. J Natl Cancer Inst 1975; 55(4): 977-81.

29. Taylor DR, Poulton R, Moffitt TE et al. The respiratory effects of cannabis dependence in young adults. Addiction 2000; 95(11): 1669-77.

30. Shay AH, Choi R, Whittaker K et al. Impairment of antimicrobial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaine. J Infect Dis 2003; 187(4): 700-4.

31. Tashkin DP, Baldwin GC, Sarafian T et al. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 2002; 42(11 Suppl): 71S-81S.

32. Feely J, Maclean D. Beta-blockers and sympathomimetics. Br Med J (Clin Res Ed) 1983; 286(6370): 1043-7.

33. Wagner JC. Abuse of drugs used to enhance athletic performance. Am J Hosp Pharm 1989; 46: 2059-67.

34. Clarkson PM, Thompson HS. Drug and sports. Research findings and limitations. Sports Med 1997; 24: 366-84.

35. Sweetman CS. Martindale: the complete drug reference. 33 ^rd ed. London, United Kingdom: Pharmaceutical Press, 2002.